Pular para o conteúdo
Merck
Todas as fotos(2)

Documentos Principais

917214

Sigma-Aldrich

BocA1V2PF1-NHPEG3-NH2

≥85%

Sinônimo(s):

tert-Butyl ((S)-1-(((S)-2-((S)-2-(((S)-1-amino-13-oxo-15-phenyl-3,6,9-trioxa-12-azapentadecan-14-yl)carbamoyl)pyrrolidin-1-yl)-1-cyclohexyl-2-oxoethyl)amino)-1-oxopropan-2-yl)carbamate, AVP conjugate for IAP-mediated protein degrader development, Protein degrader building block for PROTAC® research

Faça loginpara ver os preços organizacionais e de contrato

Selecione um tamanho

50 MG
R$ 3.448,00

R$ 3.448,00


Check Cart for Availability

Solicite uma grande encomenda

Selecione um tamanho

Alterar visualização
50 MG
R$ 3.448,00

About This Item

Fórmula empírica (Notação de Hill):
C38H62N6O9
Peso molecular:
746.93
Número MDL:
Código UNSPSC:
41116105
NACRES:
NA.22

R$ 3.448,00


Check Cart for Availability

Solicite uma grande encomenda

ligand

BocA1V2PF1

Nível de qualidade

Ensaio

≥85%

Formulário

powder

adequação da reação

reactivity: carboxyl reactive
reagent type: ligand-linker conjugate

grupo funcional

amine

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

C[C@H](NC(OC(C)(C)C)=O)C(N[C@H](C(N1CCC[C@H]1C(N[C@H](C(NCCOCCOCCOCCN)=O)CC2=CC=CC=C2)=O)=O)C3CCCCC3)=O

chave InChI

OASZCJLPYPSNDH-QJANCWQKSA-N

Aplicação

Protein degrader building block BocA1V2PF1-NHPEG3-NH2 enables the synthesis of molecules for targeted protein degradation and SNIPER (specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein erasers) technology. Developed in partnership with ComInnex, this conjugate contains an in silico-derived IAP-recruiting ligand, an alkyl-chain crosslinker, and a pendant amine for reactivity with an acid on a target warhead. Because even slight alterations in ligands and crosslinkers can affect ternary complex formation between the target, E3 ligase, and protein degrader, many analogs are prepared to screen for optimal target degradation. When used with other protein degrader building blocks with a terminal amine, including CRBN and VHL targeted, parallel synthesis can be used to more quickly generate SNIPER and PROTAC® degrader libraries that feature variation in crosslinker length, composition, and E3 ligase ligand. Learn more about the novel IAP ligands generated through virtual screening of AVP mimetics in our Technology Spotlight.

Building blocks in this series:
916978 BocA1V2PF1
917966 BocA1V2PF1-NHC6-NH2
916706 BocA1V2PF1-NHC10-NH2
916951 BocA1V2PF1-NHPEG1-NH2
917214 BocA1V2PF1-NHPEG3-NH2

Technology Spotlight: Degrader Building Blocks with Inhibitor of Apoptosis Protein (IAP) In Silico-Derived Ligands

Informações legais

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

produto relacionado

Nº do produto
Descrição
Preços

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Junjie Liu et al.
Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy, 31(3), 332-341 (2020-11-05)
This paper evaluates the efficacy and safety of repeat hepatic resection and radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. We retrieved and collected all relevant articles from the inception to 8 March 2020. After data extraction, we conducted
Nobumichi Ohoka et al.
The Journal of biological chemistry, 292(11), 4556-4570 (2017-02-06)
Many diseases, especially cancers, result from aberrant or overexpression of pathogenic proteins. Specific inhibitors against these proteins have shown remarkable therapeutic effects, but these are limited mainly to enzymes. An alternative approach that may have utility in drug development relies
Mikihiko Naito et al.
Drug discovery today. Technologies, 31, 35-42 (2019-06-16)
The induction of protein degradation by chimeric small molecules represented by proteolysis-targeting chimeras (PROTACs) is an emerging approach for novel drug development. We have developed a series of chimeric molecules termed specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein

Artigos

Targeted protein degradation (TPD) is an emerging strategy that uses small molecules to hijack endogenous proteolysis systems to degrade disease-relevant proteins and thus reduce their abundance in cells.

Targeted protein degradation reduces disease-relevant proteins in cells using small molecules, hijacking endogenous proteolysis systems.

Plate of 80 ligands against E3 ligase IAP designed by ComInnex; allows creation of bifunctional targeted protein degraders or molecular glues.

Protein Degrader Building Blocks are a collection of crosslinker-E3 ligand conjugates with a pendant functional group for covalent linkage to a target ligand.

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica